Compare VRSK & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRSK | RVMD |
|---|---|---|
| Founded | 1971 | 2014 |
| Country | United States | United States |
| Employees | N/A | 883 |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.7B | 30.1B |
| IPO Year | 2008 | N/A |
| Metric | VRSK | RVMD |
|---|---|---|
| Price | $194.85 | $187.53 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 19 |
| Target Price | ★ $259.38 | $140.84 |
| AVG Volume (30 Days) | 1.7M | ★ 1.8M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.06% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.73 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.68 | N/A |
| Revenue Next Year | $6.74 | $533.02 |
| P/E Ratio | $115.07 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $155.94 | $34.00 |
| 52 Week High | $276.19 | $194.56 |
| Indicator | VRSK | RVMD |
|---|---|---|
| Relative Strength Index (RSI) | 51.00 | 55.41 |
| Support Level | $194.77 | $176.00 |
| Resistance Level | $223.60 | $193.83 |
| Average True Range (ATR) | 7.40 | 7.45 |
| MACD | -0.07 | -0.96 |
| Stochastic Oscillator | 20.23 | 58.24 |
Verisk is a leading data, analytics, and technology provider for property-casualty insurers. Verisk traces its history to Insurance Services Office, a nonprofit advisory organization founded in 1971 by US P&C insurers. ISO was formed as an association of insurance companies to assist with a variety of insurance use cases, such as reporting to regulators, defining policies, and determining independent premium rates. As the firm expanded its use cases, it became a for-profit company, renamed Verisk, and went public in 2009. Verisk's single segment (insurance) provides underwriting solutions, including forms, rules, loss costs, and catastrophe modeling. For claims, Verisk's solutions include property repair estimates and antifraud tools. About 83% of Verisk's revenue is US-based.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.